GammaDelta Therapeutics aims to harness the unique properties of γδ T cells to improve patient outcomes and survival rates among patients with haematological malignancies and solid tumours.
Our mission is to deliver highly effective allogeneic immunotherapies based on the unique properties of Vδ1+ T cells with potential to provide additional benefits towards patient survival in the treatment of cancers. Our proprietary iso...
GammaDelta Therapeutics aims to harness the unique properties of γδ T cells to improve patient outcomes and survival rates among patients with haematological malignancies and solid tumours.
Our mission is to deliver highly effective allogeneic immunotherapies based on the unique properties of Vδ1+ T cells with potential to provide additional benefits towards patient survival in the treatment of cancers. Our proprietary isolation and expansion protocols have the ability to selectively generate Vδ1+ T cell populations suitable for clinical application.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.